Korean J Clin Pharm.  2017 Jun;27(2):99-104. 10.24304/kjcp.2017.27.2.99.

Comparisons of Efficacy between Dapagliflozin and Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus Patients

Affiliations
  • 1Graduate School of Clinical & Public Health Convergence, Ewha Womans University, Seoul 03760, Republic of Korea. hsgwak@ewha.ac.kr
  • 2Division of Pharmaceutical Services, Asan Medical Center, Seoul 05535, Republic of Korea.
  • 3College of Pharmacy, Wonkang University, Iksan 54538, Republic of Korea.
  • 4College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.

Abstract


OBJECTIVE
This study aimed to compare effects on glycemic control and weight loss between the metformin/dapagliflozin combination and the metformin/sitagliptin combination in type 2 diabetic patients.
METHODS
This study retrospectively reviewed the medical records, from January 1(st) 2015 to March 31(st) 2016, of type 2 diabetic patients who were older than 18 and were prescribed with dapagliflozin or sitagliptin in combination with metformin. Hemoglobin A(1c) (HbA(1c)) levels and weights were measured every 3 months.
RESULTS
The dapagliflozin group showed a greater decrease in HbA(1c) levels after 3 months (-0.75% vs. 0.01%, P<0.001), 6 months (-0.36% vs. 0.08%, P=0.029), and 9 months (-0.53% vs. 0.08%, P=0.046) compared to the sitagliptin group. Also, the dapagliflozin group showed a greater significant decrease in the rate of change in HbA1c levels after 3 months (-0.09 vs. 0.01, P<0.001), 6 months (-0.04 vs. 0.01, P=0.031), 9 months (-0.07 vs. 0.02, P=0.029), and 12 months (-0.05 vs. 0.05, P=0.047). Furthermore, the dapagliflozin group showed a greater decrease in amount of weight change after 3 months (-2.46 kg vs. 0.37 kg, P<0.001), 6 months (-3.02 kg vs. 0.13 kg, P<0.001), and 9 months (-2.27 kg vs. 0.50 kg, P=0.002). Finally, the dapagliflozin group showed a greater decrease in the rate of change in weight after 3 months (-3.10% vs. 0.52%, P<0.001), 6 months (-3.83% vs. 0.21%, P<0.001), 9 months (-2.84% vs. 0.79%, P=0.002), and 12 months (-4.91% vs. 0.44%, P<0.001).
CONCLUSION
It was concluded that dapagliflozin is more effective than sitagliptin for type 2 diabetic patients.

Keyword

Dapagliflozin; sitagliptin; metformin; glycemic control; weight loss

MeSH Terms

Diabetes Mellitus, Type 2*
Humans
Medical Records
Metformin*
Retrospective Studies
Sitagliptin Phosphate*
Weight Loss
Weights and Measures
Metformin
Sitagliptin Phosphate
Full Text Links
  • KJCP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr